Biodesix, Inc.
$24.72+$1.86 (+8.14%)
Biodesix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.68% below the high.
NASDAQ · BDMD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Baird Medical Investment Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 94.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Baird Medical Investment Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive management of a diverse array of benign and malignant tumors, notably targeting thyroid nodules, hepatic carcinomas, pulmonary cancers, and mammary lesions. The organization was established in 2012, with its corporate headquarters situated in Guangzhou, China.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$24.72+$1.86 (+8.14%)
Biodesix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.68% below the high.
$2.62-$0.01 (-0.38%)
OnKure Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.3% below the high.
$8.11-$0.31 (-3.68%)
electroCore, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.14% below the high.
$9.07-$0.15 (-1.63%)
FibroGen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.68% below the high.
$0.54+$0.01 (+1.34%)
HeartBeam, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.53% below the high.
$4.40-$0.84 (-16.03%)
Cytosorbents Corporation’s quoted price sits in the lower half of its reported 52-week range, 74.12% below the high.
$0.97+$0.11 (+12.96%)
NeuroOne Medical Technologies Corporation’s quoted price sits in the lower half of its reported 52-week range, 84.15% below the high.
$0.08+$0.04 (+121.94%)
Inotiv, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.73% below the high.